Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Enjoying this discussion over the worthlessness or value of RCPIQ!
The big question is why anyone would offer to pay $700 to buy 1.75 million shares of a worthless stock @ .ooo4. This same question has persisted for the last 3 1/2 years since RCPI went the Chapter 7 route.
Looks like we will not have any answers until RCPIQ is delisted or MYMD reopens its website.
I have no idea why MYMD is hiding behind the "updating" curtain, but it may be that they are looking to demonstrate the effectiveness of their MYMD-1 against Hashimoto's Thyroiditis on persons identified with the disease in Phase 2 FDA trials. With that in hand they probably would be free to license major pharmaceutical companies in the areas listed in the previous message.
US20200061043A1 Patent SUMMARY
(0002) a method of treating cancer
(0003) a method of treating an autoimmune disorder
(0004) a method of treating autism
(0005) a method of treating a viral infection
(0006) a method of treating hypertension or high blood pressure
(0007) a method of treating a disorder associated with chronic inflammation
(0008) a method of treating a disorder associated with increased levels of
levels of hydrogen peroxide and/or other Reactive Oxygen Species
(0009) a method of treating a disorder associated with abnormal expression
or activity of dual-specificity tyrosine phosphorylation-regulated
Kinase1A (DYRK1A)
MYMD PHARMA PART 3 "ABOUT US"
"In vitro and in vivo murine model studies have demonstrated that without measurable toxicity, MYMD-1:
Regulates Th1 and the release of TNF-a in a dose dependent manner
Ameliorates autoimmune thyroiditis
Prevents and reverses multiple sclerosis
Improves vital health signs
Reverses aging, as measured by key markers for cellular aging and by murine longevity studies."
Jonnie Williams has applied for numerous US and World patents including the latest published 2020-02-27, Entitled "Pharmaceutical Salts of Isomyosmine And Pharmaceutical Compositions Containing Same" which is a mind blower. Check Google Patents for US20200061043A1.
MYMD PHARMA PART 2 "About Us"
"Work performed at the Johns Hopkins School of Medicine, recently published in The Journal of Immunology, has shown that MYMD-1 specifically targets subsets of T lymphocytes called effector T cells by reducing their activity. Effector T cells are involved in mediating a broad spectrum of autoimmune diseases. The studies further showed that MYMD-1 has a broad spectrum effect on the immunometabolic system including, suppressing in vitro the production of the pro-inflammatory cytokine TNF-alpha by effector T helper 1 T lymphocytes (Th1 cells), reducing nitrite and increasing hydrogen sulfide. Multiple mouse disease models have demonstrated that MYMD-1 decreased the incidence and severity of MS, and significantly extended longevity and reversed signs of aging."
"MYMD-1 is a small molecule with a benign safety profile as demonstrated in pre-clinical studies. Phase 1 human safety and dosing trials are scheduled for completion in 2019"
"As an immunometabolic regulator, MYMD-1 uniquely targets the rate of cellular oxidation as the underlying cause (as opposed to the symptom) of many currently uncured diseases. Accordingly, the therapeutic scope of our lead candidate is being expanded through ongoing preclinical studies focused on additional age-related diseases, virtually all autoimmune diseases, Alzheimer's disease, various cancers and heart disease."
Relax 1man
I did not say in my message that MYMD will takeover RCPIQ. What I was referring to is the fact that the individuals behind RCPIQ are the same individuals behind MYMD. MYMD was incorporated in Nov. 2014 to promote isomyosmine. RCPIQ was promoting anatabine, but was in trouble and went to Chapter 7 in Sept. 2016.
When RCPIQ is gone, MYMD will be there to continue pursuing the medical benefits of the nicotinic molecules!
Since MYMD Pharma will eventually replace RCPIQ , I am going to submit what MYMD was saying about itself before they closed the curtain on their website.
"ABOUT US" "MYMD Pharma is a privately owned and funded clinical stage biotech company. MYMD has discovered, patent protected and is developing a novel, first in class drug (MYMD-1) to treat disease and aging at the root cause: immunometabolic dysfunction.
It is established that a balanced immunometabolic system is essential to maintaining healthy homeostasis; however, under stress or as we age, this complex system can commonly enter a state of dysfunction causing disease and aging. MYMD-1 is a novel drug platform that is being developed to treat a broad range of conditions, including autoimmune disease, cardiovascular disease, neurological disease and aging by addressing dysfunction of the immunometabolic system.
While the landscape of healthcare in the United States continues to change, at MYMD we continue to move science forward by arming researchers with creative solutions THAT CHALLENGE previous scientific understandings of immuno-metabolic systems in the body.
This year we have presented our investigational new drug (IND) application for our lead candidate, MYMD-1, to the US Food and Drug Administration. We are proceeding with a Phase 1 trial in healthy human volunteers for the treatment of Hashimoto's Thyroiditis. In addition to this Phase 1 trial, we are developing preclinical programs for other devastating conditions. We believe our unique approach could revolutionize treatment for many autoimmune disorders where the underlying pathology is driven or enhanced by the regulation of immuno-metabolic systems. These disorders often have a high unmet need for safe, effective therapies."
MORE TOMORROW
Value
The "bad news" is that there is absolutely no information on what MYMD Pharmaceuticals will or will not do, if anything. The website continues to show the "Will Be Back Soon" message they have displayed for many months.
The musings mentioned here about RCPIQ shareholders receiving MYMD shares for their RCPIQ shares is strictly my wishful thinking about what I would like to see.
In reality, in these cases the old stockholders usually get stiffed and go away emptyhanded, and the new stockholders get all the gravy!
mick
Yes this is a Florida private company which when they had an open website were freely open about who they were and what they planned to do. They had just applied to the FDA for a New Drug Application for their drug "MYMD-1", and expected to complete Phase 1 "drug safety and dosing" by the end of 2019.
Why they suspended the website, they only know. My guess is they went behind the Wizard of Oz curtain to shield what they were doing until they were ready to go public. Time will tell.
The blocked website has been around for about 6 months!
Was hoping MYMD Pharma would reverse merge into RCPIQ to become a public company on the cheap. Interestingly, the blocked out MYMD Pharma website does not seem to be accessible as of today!
Meanwhile, RCPIQ's private company spinoff, MYMD Pharmaceuticals, continues to proceed with its NDA with the FDA under the cover of a blocked out website! No way of knowing where they are in this process, or what significance it might have for us.
This "key patent" applied for in Australia has been assigned to Philip Morris, and should offer no benefit to RCPIQ.
It takes about 30 seconds to load!
Where does that leave us with the RCPIQ Chapter 7 bankruptcy?
The "idiot" that "always blocked up the upward movement" may be the same idiot that is trying to accumulate as many shares as possible at the lowest possible price.
Anyone know if MYMD Pharma's current dealings with the FDA are available for public viewing?
Just found new patent application US202000610443A1 assigned to MYMD published 2/27/2020 in which the abstract includes "In other aspects, isomyosmine is administered to treat viral infections"....
Will this ever end!
Might isomyosmine have a place in dealing with the coronavirus epidemic?????
In some aspects, a pharmaceutical composition containing isomyosmine is administered to an individual to treat a viral infection. In one example, the virus is human immunodeficiency virus (HIV). In another example, the virus is herpes simplex virus (HSV). In yet another example, the virus is human papillomavirus (HPV). Low-risk mucosal HPVs such as HPV-6 and HPV-11 cause genital warts (condyloma accuminata), whereas the high-risk HPVs cause squamous intraepithelial lesions that can progress to invasive squamous cell carcinoma. The vast majority of human cervical cancers are associated with high-risk HPV infections. HPV-16 is by far the most prevalent mucosal high-risk HPV type, followed by HPV-18 and HPV-31. Approximately 20% of oral cancers, particularly oropharyngeal carcinomas in patients that lack the classical risk factors of tobacco and alcohol abuse, are also high-risk HPV positive. Other anogenital tract malignancies that are also frequently associated with high-risk HPV infections include penile and vulvovaginal cancers as well as anal carcinomas, which frequently occur in individuals with human immunodeficiency virus (HIV)-associated AIDS.
I had ordered the old anatabloc a few months ago, but they didn't have it and wanted to substitute their own brand.
It has long been my probable fantasy that there has been a significant buyer (bidder) that has been consistently accumulating RCPIQ shares below .001 per share with only a occasional purchase above that level when a significant number of shares were on the ASK. However, we will not know if that bidder is MYMD Pharma ( my suspicion) until their website resumes.
When MYMD Pharma's website was last available they said they had presented their Investigational New Drug (IND) MYMD-1 to the FDA in a Phase 1 trial to demonstrate its safety and determine probable dosages for the treatment of Hashimoto's Thyroiditis. They indicated that the Phase 1 trial should be completed in 2019.
They also indicated that ongoing preclinical studies focused on age-related diseases, virtually all autoimmune diseases, Alzheimer's disease, various cancers, and heart disease were being expanded.
No wonder that some of us here are chomping at the bit to see the MYMD website reopened!
Yahoo Finance is showing a 1 year price target of $4 for RCPIQ, but I don't have premium service so can't see if anything more is said about its outlook.
https://finance.yahoo.com/quote/RCPIQ/news?p=RCPIQ
How I wish we knew when MYMD will make its move!!!!!
Time to rev up this site now that iCAD has broken out in price on volume on a day when all major indices were down!
That takes care of Predator's anatabine from Hydrapharm, but it looks now like anatabine is only available from Lucky Vitamin which is sourced from Compound Products, whoever they are!
LadyAnge
It has been my, perhaps fantasy assumption, that RCPIQ's Chapter 7 bankruptcy application was a strategy to stop the hemorrhaging of shares resulting from a failed loan arrangement. That fantasy imagines that RCPIQ had made an arrangement with the lender under which it would become a "shell" into which MYMD Pharmaceutical would reverse merge. It would then issue MYMD shares for the shares of RCPIQ held by the lender, thereby converting the existing debt into a stock position in MYMD Pharma.
My preferred arrangement would be for MYMD to authorize 17.04 million shares, and issue to RCPIQ shareholders 1 share of its stock for each 10 shares of RCPIQ stock.
As indicated on this link, the anatabine patent to treat inflammation has been assigned to Philip Morris.
https://patents.google.com/patent/CA2794097C/en?q=anatabine&inventor=jonnie+williams&oq=jonnie+williams+anatabine
Reminder: Star Tobacco has a hearing scheduled at the bankruptcy court in Wilmington for 11:00 AM.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153370873
No bid or ask after the close. Anyone see this as significant?
Interesting ! Volume 7 million, Down 14% !
SORRY! 16:22:06?
How many shares traded at 16:42:06?
MYMD Pharmaceuticals needs to show that MYMD-1 can treat Hashimoto's Thyroiditis. That is their entryway to be "First IN Class" in this promising health breakthrough.
http://www.pharmatimes.com/news/roche_recruits_rheos_to_explore_immunometabolism_1320740
Time for MYMD Pharmaceuticals to make their next move before they get left behind! They have a promising molecule with the FDA, so lets get on with it!!
https://www.itij.com/latest/news/new-company-immunometabolism-research
Looks like we have come to a standstill with buyers and sellers refusing to meet in the middle.
SEEK
I think you may be reading it wrong. When Qty says 1, that is for 3 bottles ! When Qty says 3, that is for 9 bottles.